These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35916995)

  • 1. Cost-Benefit Analysis of Human Papillomavirus Vaccine in Iran.
    Sargazi N; Takian A; Daroudi R; Nahvijou A; Yaseri M; Ghanbari Motlagh A; Zendehdel K
    J Prev (2022); 2022 Dec; 43(6):841-857. PubMed ID: 35916995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
    Jiang Y; Ni W; Wu J
    BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model.
    Zhou L; Gu B; Wang J; Liu G; Zhang X
    BMC Public Health; 2022 Apr; 22(1):777. PubMed ID: 35436877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ; Tay SK; Teoh YL; Tok MY
    BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
    BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of human papillomavirus vaccines for the prevention of cervical cancer in India.
    Arora S; Tuffaha H
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):55-62. PubMed ID: 37132538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran.
    Yaghoubi M; Nojomi M; Vaezi A; Erfani V; Mahmoudi S; Ezoji K; Zahraei SM; Chaudhri I; Moradi-Lakeh M
    Value Health Reg Issues; 2018 May; 15():112-119. PubMed ID: 29698864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
    BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S; Zafar A; Saperi S; Amrizal M
    Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan.
    Anwari P; Debellut F; Vodicka E; Clark A; Farewar F; Zhwak ZA; Nazary D; Pecenka C; Scott LaMontagne D; Safi N
    Vaccine; 2020 Feb; 38(6):1352-1362. PubMed ID: 31870571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.
    Aponte-González J; Fajardo-Bernal L; Diaz J; Eslava-Schmalbach J; Gamboa O; Hay JW
    PLoS One; 2013; 8(11):e80639. PubMed ID: 24260441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
    Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
    Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
    Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mothers' preferences and willingness-to-pay for human papillomavirus vaccines in Iran: A discrete choice experiment study.
    Sargazi N; Takian A; Yaseri M; Daroudi R; Ghanbari Motlagh A; Nahvijou A; Zendehdel K
    Prev Med Rep; 2021 Sep; 23():101438. PubMed ID: 34189022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
    Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
    BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.